Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 3Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Healthy Adult Participants 1Colorectal Neoplasms 1Colorectal Neoplasia 1Chemotherapy Effect 1Burkitt Lymphoma 1Breast Neoplasms, Male 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 52Vincristine 32blinatumomab 30Prednisone 27Methotrexate 27Cytarabine 25Dexamethasone 23Specimen Handling 21Rituximab 20Doxorubicin 19merphos 18Mercaptopurine 18Etoposide 18fludarabine 17Biopsy 17prednylidene 16deltacortene 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16Calcium Dobesilate 16dexamethasone acetate 15dexamethasone 21-phosphate 15auricularum 15Inotuzumab Ozogamicin 15pegaspargase 14azathiopurine 14venetoclax 13Asparaginase 13Spinal Puncture 12Leucovorin 12CT-P10 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Omeprazole × 1 year × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡